Kasey Lyn Couts
Title | Asst Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
Email |  |
---|
|
|
|
Biography Valparaiso University, Valparaiso, IN | B.S. | 05/2004 | Biochemistry | University of Colorado- Boulder, Boulder, CO | Ph.D. | 12/2010 | Biochemistry |
Overview My research interests are primarily focused on understanding the development and pathobiology underlying rare melanomas (such as mucosal, acral, and ocular melanomas) in order to 1) identify risk factors to improve prevention and early detection, 2) develop novel tumor/blood diagnostics for rare melanoma subtypes, 3) establish methods for halting progression and eliminating micro-metastatic disease, and 4) improve efficacy of current therapies (targeted and immunotherapies) and develop new treatment modalities which are effective for rare melanoma patients.
Research (Kasey Couts)Jul 1, 2019 - Jun 30, 2022 Patten-Davis Foundation CU Center for Rare Melanomas Role Description: Establish a first-of-its-kind joint research and clinical center for improving care of patients with rare, non-UV associated melanomas. Role: Co-Director |
| (Kasey Couts)Mar 1, 2019 - Feb 28, 2020 CCTSI The role of BRAF fusions in melanoma anti-tumor immune responses Role Description: Determine how BRAF fusions promote anti-tumor immunotherapy responses in melanoma patients. Role: Principle Investigator |
| (Kasey Couts)Jan 1, 2018 - Dec 31, 2018 American Cancer Society Institutional Seed Grant Targeting cell cycle structural variants in acral and mucosal melanomas Role Description: Investigate cell cycle structural variants and cell cycle based therapies in acral and mucosal melanomas. Role: Principle Investigator |
| (Kasey Couts)Jul 1, 2017 - Dec 31, 2018 Cancer League of Colorado Improving targeted therapy in melanomas with BRAF fusions Role Description: Test novel combinatorial treatment strategies for BRAF fusions. Role: Principle Investigator |
| (Kasey Couts)Apr 1, 2016 - Mar 31, 2017 CCTSI Activating gene fusions as targets in malignant melanoma Role Description: Characterize gene fusions in pan-negative melanomas using melanoma PDX models. Role: Principle Investigator |
| (Kasey Couts)Jan 1, 2016 - Jun 1, 2017 Paul R. Ohara II Seed Grant Award Gene fusions as actionable therapeutic targets in acral lentiginous melanomas Role Description: Characterize and test efficacy of targeted inhibitors for gene fusions in acral melanomas. Role: Principle Investigator |
Bibliographic
-
Turner JA, Paton EL, Van Gulick R, Stefanoni D, Cendali F, Reisz J, Tobin RP, McCarter M, D'Alessandro A, Torres RM, Robinson WA, Couts KL, Schlaepfer IR. BRAF Modulates Lipid Use and Accumulation. Cancers (Basel). 2022 Apr 23; 14(9). PMID: 35565240.
-
Vorwald VM, Davis DM, Van Gulick RJ, Torphy RJ, Borgers JS, Klarquist J, Couts KL, Amato CM, Cogswell DT, Fujita M, Castleman MJ, Davis T, Lozupone C, Medina TM, Robinson WA, Gapin L, McCarter MD, Tobin RP. Circulating CD8+ mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients. Clin Transl Immunology. 2022; 11(1):e1367. PMID: 35028137.
-
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. J Invest Dermatol. 2022 Jul; 142(7):1912-1922.e7. PMID: 34942200.
-
Dart CR, Mukherjee N, Amato CM, Goulding A, MacBeth M, Van Gulick R, Couts KL, Lambert JR, Norris DA, Robinson WA, Shellman YG. A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. Pharmaceuticals (Basel). 2021 Jul 30; 14(8). PMID: 34451846.
-
Holman BN, Van Gulick RJ, Amato CM, MacBeth ML, Davies KD, Aisner DL, Robinson WA, Couts KL. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 2020 12; 30(6):562-573. PMID: 33156595.
-
Tobin RP, Jordan KR, Kapoor P, Spongberg E, Davis D, Vorwald VM, Couts KL, Gao D, Smith DE, Borgers JSW, Robinson S, Amato C, Gonzalez R, Lewis KD, Robinson WA, Borges VF, McCarter MD. IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. Front Oncol. 2019; 9:1223. PMID: 31781510.
-
Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis. 2018 09 05; 9(9):907. PMID: 30185782.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30254212.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32071067.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32513939.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34348236.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19362540.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19483722.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 27864876.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35172482.
-
Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231. PMID: 29054983.
-
Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017 06; 27(3):189-199. PMID: 28296713.
-
Nguyen N, Couts KL, Luo Y, Fujita M. Understanding melanoma stem cells. Melanoma Manag. 2015; 2(2):179-188. PMID: 26594315.
-
Lee T, Wang N, Houel S, Couts K, Old W, Ahn N. Dosage and temporal thresholds in microRNA proteomics. Mol Cell Proteomics. 2015 Feb; 14(2):289-302. PMID: 25467838.
-
Couts KL, Anderson EM, Gross MM, Sullivan K, Ahn NG. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene. 2013 Apr 11; 32(15):1959-70. PMID: 22751131.
-
Roberts EC, Hammond K, Traish AM, Resing KA, Ahn NG. Identification of G2/M targets for the MAP kinase pathway by functional proteomics. Proteomics. 2006 Aug; 6(16):4541-53. PMID: 16858730.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2006 | 1 | 2012 | 1 | 2014 | 1 | 2015 | 1 | 2017 | 2 | 2018 | 9 | 2019 | 1 | 2020 | 1 | 2021 | 2 | 2022 | 2 |
To return to the timeline, click here.
|
Couts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|